This week, we decided to learn the lessons of the Euroapi fiasco with Julie Thoin-Bousquié, reporter in the Economy department of L’Express and expert on industrial issues.
FIND ALL THE EPISODES OF THE MAGNIFIER
Listen to this episode and subscribe to La Loupe on Apple Podcasts, Spotify, Deezer, Google Podcasts, Addict Podcast And Amazon Music.
The team: Charlotte Baris (presentation), Mathias Penguilly (writing), Miléna Rossi (editing) and Jules Krot (directing)
Music and dressing: Emmanuel Herschon/Studio Torrent
Image credits: Christophe ARCHAMBAULT / AFP
How to listen to a podcast? follow the leader.
Charlotte Baris: Covid-19 has indeed revealed our dependence on Asian drug factories and American laboratories. And since then, European public authorities have been campaigning for the relocation of our medicine production. At the same time, all the large groups have decided to keep only their most lucrative activities and shed several subsidiaries. On the one hand, the search for sovereignty on the other, an imperative for profitability. This balancing act is what Sanofi has undertaken since the pandemic.
While Pfizer and Moderna launched their messenger RNA vaccines around the world, Sanofi was relegated to the rank of subcontractor. Since then, the company has decided to focus on certain of the most lucrative activities (oncology, vaccination or rare pathologies for example). But this refocusing is being carried out to the detriment of other branches from which Sanofi has decided to separate. And in particular its “general public” division (which produces Doliprane).
As you can imagine, a sale of this magnitude cannot be carried out just anyhow. The problem is that there is a precedent. In 2022, Sanofi has already sold six factories, brought together under the name Euroapi. And today they are experiencing great difficulties. As the sale of Sanofi’s “general public” division comes to fruition, we look back at the Euroapi fiasco with a journalist who studied the matter from every angle.
For further :
Serge Weinberg, president of Sanofi: “Health sovereignty is not free”
Choose France: Sanofi’s massive investment in drug production
Medicines, vaccines… Sanofi’s new strategy